TY - JOUR
T1 - Cancer-related cognitive impairment in non-CNS cancer patients
T2 - Targeted review and future action plans in Europe
AU - European Cancer and Cognition Consortium (ECCC)
AU - Sleurs, Charlotte
AU - Amidi, Ali
AU - Wu, Lisa M
AU - Kiesl, David
AU - Zimmer, Philipp
AU - Lange, Marie
AU - Rogiers, Anne
AU - Giffard, Benedicte
AU - Binarelli, Giulia
AU - Borghgraef, Cindy
AU - Deprez, Sabine
AU - Duivon, Mylène
AU - De Ruiter, Michiel
AU - Schagen, Sanne
AU - Ahmed-Lecheheb, Djihane
AU - Castel, Hélène
AU - Buskbjerg, Cecilie R
AU - Dos Santos, Mélanie
AU - Joly, Florence
AU - Perrier, Joy
N1 - Funding Information:
This work was supported by the Région Normandie (Réseaux d’Intérêts Normands, RIN) and the Ligue contre le Cancer – Normandie . This work was also supported by the Ligue nationale contre le cancer (Cancer and Cognition platform), and the Fonds Européens du Développement Régional (FEDER, project CancerCOG), Normandy Rouen University and Inserm.
PY - 2022
Y1 - 2022
N2 - Cancer-related cognitive impairment (CRCI) has increasingly been identified over the last two decades in non-CNS system cancer patients. Across Europe, researchers have contributed to this effort by developing preclinical models, exploring underlying mechanisms and assessing cognitive and quality of life changes. The ultimate goal is to develop interventions to treat patients experiencing CRCI. To do so, new challenges need to be addressed requiring the implementation of multidisciplinary research groups. In this consensus paper, we summarize the state of the art in the field of CRCI combined with the future challenges and action plans in Europe. These challenges include data sharing/pooling, standardization of assessments as well as assessing additional biomarkers and neuroimaging investigations, notably through translational studies. We conclude this position paper with specific actions for Europe based on shared scientific expert opinion and stakeholders involved in the Innovative Partnership for Action Against Cancer, with a particular focus on cognitive intervention programs.
AB - Cancer-related cognitive impairment (CRCI) has increasingly been identified over the last two decades in non-CNS system cancer patients. Across Europe, researchers have contributed to this effort by developing preclinical models, exploring underlying mechanisms and assessing cognitive and quality of life changes. The ultimate goal is to develop interventions to treat patients experiencing CRCI. To do so, new challenges need to be addressed requiring the implementation of multidisciplinary research groups. In this consensus paper, we summarize the state of the art in the field of CRCI combined with the future challenges and action plans in Europe. These challenges include data sharing/pooling, standardization of assessments as well as assessing additional biomarkers and neuroimaging investigations, notably through translational studies. We conclude this position paper with specific actions for Europe based on shared scientific expert opinion and stakeholders involved in the Innovative Partnership for Action Against Cancer, with a particular focus on cognitive intervention programs.
KW - Humans
KW - Quality of Life
KW - Cognitive Dysfunction/diagnosis
KW - Neoplasms/therapy
KW - Biomarkers
KW - Europe
UR - http://www.scopus.com/inward/record.url?scp=85140044544&partnerID=8YFLogxK
U2 - 10.1016/j.critrevonc.2022.103859
DO - 10.1016/j.critrevonc.2022.103859
M3 - Review article
C2 - 36257539
SN - 1040-8428
VL - 180
JO - Critical Reviews in Oncology/Hematology
JF - Critical Reviews in Oncology/Hematology
M1 - 103859
ER -